Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) results from 925 treated cases of bacterial infections of the urinary organs were documented. The analysis revealed the following conclusions: 1. On the basis of all the assessable cases, there was no clinical effect in less than 10% of patients and no bacteriological effect in only 13% of patients. The therapeutic response was clinically good in 76% and bacteriologically good in 68% of the patients. The rest of the patients showed a fair clinical response, that is to say they showed a definite improvement in the clinical picture, or some bacteriological response, i.e. a definite reduction in the organism counts or, in mixed infections, not all the strains of pathogen were eradicated. 2. There was a higher success rate in acute urinary tract infections which had not previously been treated than in chronic or previously treated cases. 3. The therapeutic results in the principal indications were as follows: Pyelonephritis: 73.9% good and 16.5% fair effect clinically; 63.6% good and 21.6% some effect bacteriologically. Pyelitis: 81.1% good and 18.9% fair effect clinically; 70.4% good and 25.9% some effect bacteriologically. Cystitis: 81.3% good and 8.6% fair effect clinically; 68.9% good and 17.6% some effect bacteriologically. Postoperative urinary tract infections: 98% good effect clinically and bacteriologically. Infections of the urinary organs (not specified in more detail): 71.8% good and 16.1% fair effect clinically; 65.0% good and 18.8% some effect bacteriologically.
 ...
PMID:[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123). 2. Results of a multicenter clinical trial of CN 3123 in infections of the kidneys and urinary tract]. 94 28

We studied the nutritional and metabolic features of Eubacterium suis, an anaerobic animal pathogen that causes cystitis and pyelonephritis in pigs. Peptone-yeast extract-starch (PYS) medium, which contained Trypticase (BBL Microbiology Systems), yeast extract, starch, minerals, cysteine, and sodium carbonate, was shown to support excellent growth of this organism (absorbance at 600 nm = 1.8). Growth was considerably less (absorbance at 600 nm = 0.6) when the starch in the medium was replaced by maltose. Formate, acetate, and ethanol were the major products of fermentation of starch or maltose. The organism appears to require a fermentable carbohydrate for growth since the deletion of starch from PYS resulted in a negligible amount of growth. Growth decreased by approximately 20% when CO2 was rigorously excluded from PYS minus Na2CO3. The deletion of only yeast extract from PYS resulted in a decrease in growth of about 75%, and the simultaneous deletion of both yeast extract and Trypticase resulted in negligible growth. When the yeast extract in PYS was replaced by a defined mixture of purine and pyrimidine bases, vitamins, and amino acids, growth was greater than or equal to 80% that observed in PYS. The deletion of Trypticase from this medium resulted in no detectable growth, suggesting a possible peptide requirement for E. suis growth. Good growth (absorbance at 600 nm = 1.4) was obtained when adenine and uracil were substituted for the mixture of purine and pyrimidine bases in modified PYS; the substitution of pyridoxal, riboflavin, and nicotinic acid for the vitamin mixture gave comparable growth. The nutritional requirement of E. suis apparently reflect the fact that the organism adapts to its natural niche by doing away with certain biosynthetic capabilities which it does not seem to require.
 ...
PMID:Nutritional and metabolic features of Eubacterium suis. 680 18

In 100 patients with urinary tract infections the new benzyl-pyrimidine/sulphonamide combination Co-tetroxazin (Sterinor) was tested concerning its in vitro and in vivo action. In spite of the heterogenous cases (pyelonephritis 16%, obstructions 15%, prostatitis respectively urethritis 12% and cystitis 53%) and the relatively high average age (about 40% above the age of 60) a high therapeutic success was achieved. The clinical symptomatology improved up to 96% (respectively 83% without anymore pathological findings). This in vivo action correlated very well with the in vitro action in the agar diffusion test: fully sensitive 79%, moderately sensitive 15% and resistant only 6%. It is worth mentioning that the in vivo results with Sterinor were obtained with only 1/3 of the usual substance load (dosis) of the other benzylpyrimidine/sulphonamide combinations. This is due to the more favourable pharmacokinetic properties. Particularly in chronic patients, multi-morbidity and in elder patients this is clinically relevant. With this proven comparable clinical effect Co-tetroxazin is to be specified therefore to be more effective pharmacologically.
 ...
PMID:[Antibacterial treatment of urinary tract infections with co-tetroxazin (sterinor)]. 701 96

In prokaryotes and eukaryotes, phosphotransfer represents a common mechanism to regulate cellular functions. Recent work revealed that modulation of cellular processes by eukaryote-like serine/threonine kinases (STKs) and phosphatases (STPs) are widespread in bacteria. During the last two years, first evidence on the role of Ser/Thr phosphorylation/dephosphorylation in Staphylococcus aureus has emerged leading to the identification of a functional STK and corresponding STP. Due to homology to known STKs/STPs in other bacterial species the kinase was designated PknB or alternatively Stk/Stk1, and the phosphatase Stp. The role of these enzymes in S. aureus has been examined by use of knock-out mutants and a kinase-overexpressing strain. These studies uncovered PknB/Stk and Stp as modulators of cell wall structure and susceptibility to cell wall-acting antibiotics such as certain beta-lactams and tunicamycin. By utilizing transcriptional profile analysis a strong regulatory impact of PknB/Stk on the expression of genes encoding proteins which are involved in purine and pyrimidine biosynthesis, cell wall metabolism, autolysis, and glutamine synthesis could be identified. Moreover, PknB/Stk is able to phosphorylate MgrA, thereby regulating activity of the efflux pump NorA. In a mouse pyelonephritis model PknB/Stk has been shown to play a role in virulence. Overall, Ser/Thr phosphorylation/dephosphorylation is a common theme in regulation of cellular functions determining metabolic activity and virulence also in the major human pathogen S. aureus.
 ...
PMID:The impact of serine/threonine phosphorylation in Staphylococcus aureus. 1978 79